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Within medical research, a ‘placebo’ is commonly under-
stood as an object used in randomised controlled trials to 
control for, among other factors, the psychological, social 
and cultural effects of treatment. Our focus is on the clinical 
use of placebo treatment, understood broadly as when 
something like these factors are deliberately exploited by 
healthcare professionals during treatment, outside the con-
text of a trial. The clinical placebo has a long history 
(Shapiro and Shapiro, 1997), but current understanding has 
developed from the early notion of an ‘ineffective’ treat-
ment used to please patients, to one of an active agent in its 
own right (Kaptchuk, 1998; Kaptchuk and Miller, 2015; 
Kerr et al., 2008; Wolff et al., [1946] 2013). In this study, 
we discursively explore public perspectives on clinical pla-
cebos and their effects.
There is increasing evidence that placebo treatment 
may have clinical utility (Benedetti, 2014; Evers et al., 
2018; Vase et al., 2002; Wampold et al., 2005). For exam-
ple, treating pain by inducing the production of endoge-
nous opiates (Benedetti, 1996; Levine et al., 1978) and 
treating Parkinson’s disease by inducing the release of 
endogenous dopamine (De la Fuente-Fernández et al., 
2001). Moreover, healthcare professionals are known to 
use placebo treatment in clinical practice for different rea-
sons such as to improve care, manage patients’ expecta-
tions and cope with uncertainty (Bishop et al., 2014b; 
Comaroff, 1976; Tilburt et al., 2008).
However, although placebo treatment is common, its 
frequency of use and healthcare professionals’ attitudes 
towards placebo treatment vary significantly (Fässler 
et al., 2010; Linde et al., 2018). Furthermore, despite 
potential clinical utility, there are considerable definitional 
and ethical disagreements surrounding placebos and their 
effects (Alfano, 2015; Blease, 2011; Miller and Brody, 
2011; Miller and Colloca, 2009). For example, placebo 
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effects have been conceived as follows: the psychological 
effects of ‘inert’ substances (Beecher, 1955); the psycho-
social context of treatment (Colloca and Miller, 2011); the 
effects of healing rituals and symbols (Brown, 2013; 
Kaptchuk and Miller, 2015; Miller and Colloca, 2010) and 
the response to enculturated meaning (Moerman, 2002). At 
present, some promising attempts at a synthesis notwith-
standing (e.g. Howick, 2017; Ongaro and Ward, 2017), an 
integrative theory of placebos does not yet exist (Miller 
et al., 2009).
Compounding this lack of consensus, the increasingly 
nuanced understanding of placebos and their effects in the 
research community is becoming progressively detached 
from public perspectives. This is especially significant for a 
process that, as noted above, is increasingly understood as 
entangled with meaning and social interaction (Moerman, 
2002; Moerman and Jonas, 2002). If, as seems reasonable, 
placebo effects cannot be explained by the effects of an 
‘inert’ substance, then the focus should shift towards under-
standing how patients interpret something like this phenom-
enon (Moerman, 2013).
The definitional and ethical disagreements around pla-
cebos and their effects are evident in public perspectives. 
For example, some patients take a consequentialist view, 
stating that placebos are acceptable as long as it helps. 
Others state that placebos are unethical because they, sup-
posedly, require deception, violating a deontological com-
mitment to patient autonomy (Bishop et al., 2014a; Feffer 
et al., 2016). In addition, although there is an increasing 
focus on patients’ perspectives (Hull et al., 2013; Lynoe 
et al., 1993; Tandjung et al., 2014), research in this area is 
underdeveloped.
Given the ambiguity in placebo studies research, partic-
ularly regarding the views of healthcare professionals, 
researchers conducted a study exploring placebo use by 
general practitioners (GPs) in the United Kingdom (Howick 
et al., 2013). This included findings that 77 percent of sur-
veyed GPs used placebos – defined very widely – at least 
once a week and that most respondents believed placebos 
– again defined very widely – to be ethical in some circum-
stances. These findings attracted significant media atten-
tion from major online news organisations.
Perhaps due to the contentious nature of the debate, the 
news articles resulted in many readers commenting on the 
respective websites. These comments give an indication of 
public perspectives on placebos and their effects; com-
mentators were largely responding to the findings of the 
study, interpreted by journalists, or to the placebo phenom-
enon more generally. We conducted a discursive explora-
tion of these comments, aiming to understand (1) how 
members of the public conceptualise placebos and their 
effects; (2) how the ethical status of placebo use is publicly 
negotiated and (3) how these conceptualisations and ethi-
cal negotiations might open up and close down potential 
modes of clinical practice.
Method
The data
Data were collected from internet comments on six UK 
news articles responding to Howick et al.’s (2013) study on 
placebo use by UK GPs. The included news organisations 
reflect a political cross-section of the mainstream UK 
media. Howick et al.’s study was published in March 2013, 
as were the news articles. Data collection was restricted to 
UK organisations to set the conditions for deeper socio-
cultural analysis.
The data consist 930 comments, over six sources, cover-
ing 55,410 words. The typical length of each comment is 
between 40 and 70 words. One data source dominated, with 
445 comments. The other five sources have 202, 176, 63, 
43 and 1 comment, respectively.
The data are located on popular, open-access online 
news sites; therefore, it is reasonable to assume that the 
data are already public. However, in the context of inter-
net-mediated research, the distinction between private 
and public space is complex (British Psychological 
Society, 2013). Although the data can reasonably be con-
sidered public, commentators did not contribute their 
opinions with the explicit understanding that they would 
be used for research or disseminated in a different con-
text. Therefore, the specific news articles are not named 
in this study, and all pseudonyms used by online com-
mentators are anonymised to better protect their confi-
dentiality: this is also stipulated in the ethical clearance 
given for this study. In the analysis, each data source is 
identified by a letter (A, B, C, D, E, F). Within each data 
source, commentators are then sequentially numbered 
(A1, A2, A3,…, etc.).
Mode of analysis
Discourse analysis can be understood broadly as a method 
of analysing the content, structure and performance of lan-
guage. In psychology, it is broadly split into two approaches: 
‘discursive psychology’ is concerned with discourse prac-
tices, what people do with language; and ‘critical discourse 
analysis’ (CDA) concentrates on the discursive resources 
supporting language, what sort of being-in-the-world is 
available to people (Willig, 2013). Given the contention 
surrounding placebos and their effects and the importance 
of socio-cultural factors in their comprehension, we used 
CDA, as it allowed us to analyse the structures of meaning 
behind the placebo phenomenon and how people utilise the 
phenomenon in practice.
There are a range of methodological approaches termed 
CDA (Fairclough, 2015; Parker, 2015; Wodak, 2007). Our 
approach was orientated towards exploring social struc-
tures and systems of meaning (Parker, 2015); our analysis 
was grounded in the principles of ‘an attention to history, 
theory and subjectivity’ (Parker, 2015: 18). However, 
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unlike more prevalent forms of CDA, our approach was 
mediated by a pragmatist approach to inquiry and a more 
neutral interpretation of power relations (Dewey, 1958; 
Rorty, 1982; West, 1999).
We adopted a two-phase, abductive analytic approach 
outlined by Potter and Wetherell (2010): identify patterns in 
the data and then identify functions and consequences. We 
first identified the predominant constructs of the discursive 
object in question (the placebo) through a close reading of all 
comments. We then identified the controlling metaphors, 
notions, categories and norms that support or suppress these 
constructions – the discursive resources – again through a 
close reading of the comments. Next, we explored the varia-
tions, relationships and tensions between discursive 
resources, including how they are produced and promoted. 
We did this by comparing and contrasting comments across 
the data sources and also by analysing interactions between 
commentators within each data source. We then situated the 
discursive resources and relationships between resources 
within wider ways of being-in-the-world: discourses.
After identifying patterns in the data, we focussed on the 
functions of commentators using certain discursive 
resources and identified the subject positions they took 
within discourses. Finally, we identified the consequences 
of commentators taking various subject positions within 
discourses and how this influences the intelligibility, avail-
ability and legitimacy of the discursive constructs. 
Throughout the analytic process, the integration of theory 
was not an explicit phase but incorporated throughout the 
analysis (Wodak, 2007).
Analysis
We developed two discursive constructs of the ‘placebo’: 
the dominant discursive construct of the ‘placebo pill’ and 
the less-prevalent counter-discursive construct of the ‘treat-
ment process’. We use these two constructs to frame the 
analysis.
The placebo pill
In his interpretation of the consequences of modernity, 
Anthony Giddens (1990: 21) identified the disembedding 
of social systems, whereby social relations are ‘[removed] 
from local contexts of interaction’ and restructured. One of 
the mechanisms he identified as intrinsic to this process is 
the creation of symbolic tokens, used ‘without regard to the 
specific characteristics of individuals or groups that handle 
them at any particular juncture’ (Giddens, 1990: 22). A 
common example is money, but our dominant discursive 
construct is a narrower example of such a symbolic token: 
the placebo pill.
Commentators in our study commonly conceived of a 
placebo as an ‘inert’ substance that is given to a patient. 
This common lay definition is similar to that provided by 
Henry Beecher in his famous (1955: 1602) paper, where 
placebos are ‘pharmacologically inert substances … having 
a psychological effect’. However, as other researchers have 
noted, this definition is problematic, as a ‘placebo’ cannot 
be understood coherently without reference to the patient, 
condition and therapeutic theory in question (Grünbaum, 
1986; Howick, 2017). Moreover, nothing is actually inert 
– one can treat any substance in physico-chemical terms if 
one chooses to do so – and describing a placebo in this way 
is, therefore, paradoxical. For example, ‘even the prover-
bial sugar or bread pill will prove far from inert in patients 
with insulin dependent diabetes or with gluten intolerance, 
respectively’ (Howick, 2017: 1365). Despite these issues, 
the reification of the placebo pill as a disembedded 
symbolic token dominated discussion. We identified three 
discursive resources supporting this construct: market 
exchange, individual decision-making, and biomedicine.
Market exchange
Market exchange emerged as a central resource that was 
used to support the dominant construct of the placebo pill. 
By conceiving of a placebo as an object that is given by a 
healthcare professional to a patient, the norm of market 
exchange is made available to guide human action. This 
was common across the data sources:
Data source A, Commentator 4 (A4): This is fraud. The patient 
is told that he/she is getting a certain drug and then goes and 
buys this at the chemists. But the patient is in fact paying good 
money for what is effectively water. It is considered fraud even 
to sell something that poses even as any illegal drugs! Why 
should the law be any different for legal drugs especially. 
Unbelievable, there is no hope in this country!
F2: Are you really saying that some doctors give patients 
prescriptions that the patients then take to Boots to hand over 
some of their hard-earned cash for a packet containing nothing 
but little lumps of sugar? If that is so, and it is done on a large 
scale, this practice should be exposed and the perpetrators 
prosecuted.
E5: So let me get this right. Supermarkets are vilified and a 
national crisis created when suppliers are found to have 
included horsemeat, which is harmless, in what are sold as 
beef products. But if some crew of ‘doctors’, who are too 
greedy to tell people that they don’t need treatment/pills and 
too lazy to explain why give out placebos ie fake treatments 
that deceive the public, that’s fine.
Drawing on an individualist discourse, commentators 
focussed on themselves as consumers within a market, 
whereby the aim was to ensure they were seen to get a fair 
deal from their healthcare professional. A common refrain 
was that ‘I’ll pay for my prescription with placebo money 
then’ (E4) or that ‘placebos are fine, as long as the chemist 
will accept a dud cheque for the prescription charge’ (E1). 
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To this end, commentators promoted the primacy of con-
tractual relations:
A5: If I found out I’d been given a ‘placebo’ I would be furious 
at the waste of my money on the prescription.
F1: Hang on a minute! Prescribing placebos is surely a 
conspiracy to commit fraud? After all we pay chemists £7.65, 
£7.85 from April, per prescription. Bloody expensive Smarties!
Given the existence of prescription charges in England, if 
a placebo is understood as a pill, some commentators may 
reasonably feel they are involved in a market exchange, rather 
than in the promoted institutional framework of free-at-the-
point-of-use healthcare. Moreover, if as the geographer David 
Harvey (2005: 42) posited, society is dominated by a ‘market-
based populist culture of differentiated consumerism and 
individual libertarianism’, it is not surprising that this 
appeared to inform commentators’ understanding of placebo 
treatment. However, a common criticism is that such an indi-
vidualist society negatively affects social relations, promoting 
division (Giddens, 1990; Habermas, 1984). One consequence 
of this is the second discursive resource supporting the pla-
cebo pill construct: individual decision-making.
Individual decision-making
Commentators often promoted a pejorative notion of the 
placebo, setting placebo treatment against that used for 
patients with ‘genuine’ illnesses.
A12: Probably this article refers to those who insist on being 
given something instead of sucking it up for a couple of days. 
Instead they can suck on a placebo.
A15: All that this report does is confirm my deeply held 
suspicions that many of the people who sit in the doctors’ 
waiting room have absolutely nothing wrong with them other 
than anxiety or a need for attention.
Within such an individualist discourse, healthcare was 
presented as a scarce resource by which productive work 
can be maintained: ‘We all know someone who goes to 
their GP/ hospital at every given chance. What annoys me 
is that these time wasters waste a huge amount of resources’ 
(A16). Informed by this, some commentators resisted con-
trol by the healthcare system, taking the position of self-
reliant patients making individual medical decisions.
E9: I have rarely ever taken something prescribed by my GP. 
On the occassions [sic] that I have, I have googled the drug and 
checked the dosage before taking it.
A30: I haven’t taken a medicine I didn’t research since I was 
12. If you’re being given a treatment that is mis-labelled 
chemically, that’s a crime, if you’re not researching what 
treatment you’re taking, thats your fault.
If the placebo pill, as a symbolic token, can be con-
ceived of as a disembedding mechanism, then this self- 
reliance can be understood as resistance to another such 
mechanism – expert systems. For Giddens (1990: 28) ‘expert 
systems are disembedding mechanisms because, in com-
mon with symbolic tokens, they remove social relations 
from the immediacies of context’. Some commentators 
undermined the expert system of healthcare and the social 
position of doctors, noting that ‘in any case, most GPs 
remain clueless about the finer details of pharmacology’ 
(D2) and that ‘doctors are all too ready to give out antibiot-
ics like sweeties … I always refuse them and the doctor 
gets quite confused basically says go home and get over it’ 
(E11). There is tension between, on one hand, embracing 
the symbolic token of the placebo pill, and on the other 
hand, the lack of faith in systems beyond one’s full 
comprehension.
However, although some commentators took self-reliant 
positions, others took positions as passive patients, rein-
forcing faith in expert systems:
A29: Even with the aid of the internet it is highly arrogant to 
believe you know better than a doctor who spent years training 
to be what they are.
E1: I don’t care what I’m prescribed as long as a) it works and 
b) doesn’t cause me any additional damage. Nothing wrong 
with a placebo if it does the job!
F6: I don’t care whether it’s a placebo or not, I just want to feel 
better and if tricking my mind is part of that, so be it.
Explicitly giving control to the healthcare profession in 
this way, patients ceded their role in the decision-making 
process.
Within the placebo pill construct, therefore, patients 
took active (resisting expertise) and passive (ceding con-
trol) individual decision-making positions. Both these 
approaches were informed by the third discursive resource 
supporting the placebo pill construct: biomedicine.
Biomedicine
It was common for commentators to focus on physical 
explanations at the expense of social, cultural or intersub-
jective factors. This was manifest through a number of 
techniques. First, through bifurcating nature into different 
degrees of reality, for example stating that ‘a placebo is 
NOT a drug, it is an inert substitute which is known to have 
zero direct physical effect’ (A24) or that ‘there is a plausi-
ble (though as yet unproven) theory that the placebo effect 
has a real physiological effect by stimulating the body’s 
immune system to kick fully into swing’ (A26).
Second, despite the often broad effects of pharmacologi-
cal treatment, some commentators set placebo pills against 
what they viewed as proper, ‘targeted’ drugs, for example, 
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noting that ‘when having to pay out for a prescription, you 
should have a drug that is designed for your problem’ (A7).
Third, commentators positioned placebos as ineffective 
against ‘genuine’ illnesses, viewing them merely as some-
thing to placate a patient. For example, noting that ‘the pla-
cebo would not work if the illness was genuine and the 
patient would then have to go back’ (E6) and that ‘if some-
one had a genuine illness and was prescribed a placebo, it 
would become obvious very quickly that the tablet wasn’t 
working, and they would have to go back to the doctor’ (E7).
It is not surprising that biomedicine was a dominant dis-
cursive resource. After all, to extend Quine’s (1953: 44) 
analysis to medicine, ‘the myth of physical objects is epis-
temologically superior to most in that it has proved more 
efficacious than other myths as a device for working a man-
ageable structure into the flux of experience’. Medicine has 
been historically successful precisely because it has adopted 
the myth of physical objects. However, such a myth has its 
limits. The paradox inherent in solely conceiving of place-
bos biomedically, as pills, perhaps reflects the efficacious 
limits of biomedicine’s myth of physical objects. This has 
implications for medical practice, particularly in primary 
care, where clinicians are expected to practise person-cen-
tred medicine, synthesising technical medical knowledge 
with individual patient values.
The treatment process
Although the placebo pill construct dominated, from the 
data we developed a less-prevalent counter-discursive con-
struct – the treatment process. Through this construct, the 
placebo is not conceived of as a substance, such as a pill, 
but as the whole clinical treatment process in which a mate-
rial substance may or may not be involved. We identified 
two discursive resources supporting this construct: self-
healing and shared decision-making.
Self-healing. The first discursive resource is self-healing. In 
contrast to the notion of the passive patient, prevalent in the 
placebo pill construct, commentators presented themselves 
as active actors in the treatment process, focussing on their 
own ‘self-healing’ capacity:
D4: It is my knowledge that the human body has an amazing/
powerful way of self healing. You will need some in depth 
education in understanding the amazing way in which the 
human body defends itself from viruses, bacteria and many 
other illnesses. The human body is very efficient at resolving 
it’s own health issues without medical intervention or drugs
A41: The body has a remarkable ability to heal itself. What 
placebo’s [sic] show is that we just need to convince ourselves 
that we will be better and in many cases the body does the rest. 
This is the root I think of all miracle cures. To poo poo 
placebo’s [sic] and other alternative treatments is to shut the 
door on allowing the body to heal itself.
Moreover, some commentators explicitly stated their 
views on the limitation of the biomedical model and its 
delivery within the institution of England’s National Health 
Service (NHS):
C6: But the reality is that many doctors, and the NHS structure 
itself, is such that these methods are not treated as important 
enough to prioritise because their methodologies do extend 
beyond the mechanical, they extend into psychological 
wellbeing, breathing, state of mind, awareness, none of which 
is recognised by the popular interpretation of a biomechanical 
medical model.
A35: the body is a fantastic piece of kit with great healing 
abilities. Perhaps education on this is better than perpetuating 
the myth that the medical model has all the answers, especially 
when it doesn’t, hence the article.
Others noted that ‘the body is perfectly capable of pro-
ducing its own drugs and placebo may work by illiciting 
[sic] this response’ (F8), echoing the numerous studies 
which have shown that placebo treatment can, for example, 
stimulate the production of endogenous opiates (Amanzio 
and Benedetti, 1999; Eippert et al., 2009; Gracely et al., 
1983; Pecina and Zubieta, 2018).
By accepting the limitations and fallibility of biomedical 
knowledge, commentators did not present themselves as 
active agents set against treatment – as with the self-reliant 
patient – but as patients taking an active role in treatment, 
for example, noting that ‘in many cases placebo’s [sic] work 
by enhancing your bodies healing mechanisms’ (A34). This 
broadly concurs with recent embodied and enactive accounts 
of placebo effects (Ongaro and Ward, 2017; Thompson 
et al., 2009), whereby ‘the living body is a self-producing 
and self-maintaining system that enacts or brings forth rel-
evance, and that cognitive processes belong to the relational 
domain of the living body coupled to its environment’ 
(Varela et al., [1991] 2016: xxv). Although there are a range 
of broadly enactive accounts (Hutto and Myin, 2012; 
Thompson, 2010; Varela et al., [1991] 2016), it is this notion 
of an active, autonomous organism co-dependent with its 
environment that characterised our findings. This leads to 
the second discursive resource: shared decision-making.
Shared decision-making
Developing his interpretation of the consequences of 
modernity, Giddens (1990: 79) noted that ‘people [increas-
ingly] live in circumstances in which disembedded institu-
tions, linking local practices with globalised social relations, 
organise major aspects of day-to-day life’. However, he com-
plemented the notion of disembedding with re-embedding, 
meaning ‘the reappropriation or recasting of disembedded 
social relations as to pin them down (however partially or 
transitorily) to local conditions of time and place’ (Giddens, 
1990: 79–80).
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For Giddens, the disembedding mechanisms (symbolic 
tokens or expert systems, understood together as abstract 
systems) interact with re-embedded contexts of action. One 
of these contexts is the encounter with strangers or acquaint-
ances, who serve as the access points to abstract systems. 
This encounter is one focus of commentators using the dis-
cursive resource of shared decision–making, whereby treat-
ment is understood as a joint venture between patient and 
healthcare professional:
A37: If something is being tried like this then it’s probably best 
that the Dr discusses it with the patient, in the same way they 
would if offering a new drug / therapy as part of a clinical trial. 
Would probably get better feedback that way.
C7: Not sure about placebos as I’ve never had any, as far as I 
know but agree that a good doctor can make an enormous 
difference to a patient and their illness just by listen and 
discussing the problem in a manner the patient can understand.
Developing this notion, some commentators explicitly 
took the position of patient as contributor, focussing on the 
importance of trust, for example, noting:
A38: I told my doctor and my hospital quite clearly and 
respectfully that I trust their judgement and want to be involved 
in my care, and that I always insist on knowing what the 
treatment or medicine is, why it is being given, the side-effects, 
risks, etc., and that I expect those questions to be answered 
honestly. I think everyone should be as involved in their care 
as possible.
One commentator noted that placebo treatment could be 
conducted ‘in a perfectly honest way, telling patients that 
this is a treatment that is not proved to work better than a 
placebo, but can be expected to be as good, and that 
Placebos are known to work’ (A40). This view reflects a 
trend in placebo studies research focussed on ‘open-label’ 
placebo treatment, purportedly bypassing the issue of 
deception (Carvalho et al., 2016; Colloca and Howick, 
2018; Kaptchuk et al., 2010; Kaptchuk and Miller, 2018; 
Sandler et al., 2010).
The use of shared decision-making as a discursive 
resource highlights the importance of trust in the therapeu-
tic encounter for placebo treatment, whereby ‘encounters 
with the representatives of abstract systems … take on the 
characteristics of trustworthiness associated with friend-
ship and intimacy’ (Giddens, 1990: 85). And, moreover, it 
offers a way towards understanding placebo treatment as a 
powerful, productive force bringing patients and healthcare 
professionals together within a wider communitarian 
discourse.
Through the notion of the therapeutic encounter, we can 
situate placebo treatment in a modern conception of evi-
dence-based medicine that promotes expert judgement, 
shared decision-making and a strong patient–clinician 
relationship (Charles et al., 1997; Greenhalgh et al., 2014, 
2015; Little et al., 2001; Stewart, 2005). This suggests that 
placebo treatment might sit more comfortably than previ-
ously thought within modern medical practice.
Discussion
In our discursive exploration of public perspectives on pla-
cebos and their effects, we highlight two discursive con-
structs of the placebo: the placebo pill and the treatment 
process. The consequence of the first, more dominant, con-
struct is an understanding of placebo treatment, informed 
by an individualist discourse, which divides healthcare pro-
fessionals and patients. This division, and the paradoxical 
nature of conceiving of placebos in such a way, closes 
down potential therapeutic placebo treatment by rendering 
it illogical and deceptive.
Within the second, counter-discursive construct, we 
posit that placebo treatment, informed by a communitarian 
discourse, can be conceptualised as a collective and pro-
ductive force. We suggest the placebo-as-treatment-process 
construct can be supported by conceiving of the ‘power of 
the placebo’ through the therapeutic encounter. Healthcare 
professionals can promote this notion by taking opportuni-
ties to engage patients using the counter-discursive 
resources of self-healing and shared decision-making. This 
might open up a productive and collaborative mode of clin-
ical practice by which healthcare professionals could ethi-
cally and effectively use placebo treatment. However, 
although conceiving of placebos in this way seems more 
intelligible, stretching the definition of placebo treatment 
so far does raise serious concerns for the utility of the pla-
cebo concept itself.
As we have indicated, a modern scientific understanding 
of placebos and their effects has moved from the ‘psycho-
logical’ effects of ‘inert’ substances (Beecher, 1955) 
towards accounts grounded in different theoretical back-
grounds. These include the enculturated meaning of treat-
ment (Brody, 1997; Moerman, 2002); healing rituals and 
symbols (Kaptchuk and Miller, 2015); motor-intentionality 
(Frenkel, 2008); embodiment (Thompson et al., 2009) and 
enactivism (Ongaro and Ward, 2017). However, although 
these modern theories provide interesting accounts of 
healthcare practices in general, it is difficult to see how they 
effectively delineate placebo from non-placebo. All treat-
ment processes can be conceived of in these terms and, 
therefore, they make no credible argument as to why the 
placebo is a special case. As Ongaro and Ward (2017: 529) 
themselves noted, ‘the utility of enactivism for understand-
ing placebo effects stems from its general features as a 
paradigm for understanding cognition’. Given the compet-
ing and confusing discourses that underpin the understand-
ing of placebo treatment, these theories do not offer 
convincing arguments for why we should talk about place-
bos in the first place. If we merely want to talk about the 
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potential benefits of the therapeutic encounter, why invoke 
the confusing and often paradoxical placebo in the first 
place?
This point has been made previously (Moerman, 2013; 
Nunn, 2009a, 2009b; Turner, 2012). In response, Howick 
(2017) developed Grünbaum’s (1986) notion of characteris-
tic and incidental treatment factors as a viable way to deline-
ate non-placebo from placebo. In this model, placebos are 
treatment processes remedial for a particular disorder, rela-
tive to the patient, condition and the therapeutic theory in 
question (Howick, 2017). For example, the characteristic 
factor of giving fluoxetine for depression is purportedly the 
increase of serotonin in the brain through inhibiting reup-
take. An incidental factor might be, for example, expecta-
tions about receiving the drug. In this way, one can identify 
the difference between placebo and non-placebo and make a 
case for the promotion of placebo treatment per se.
However, although the characteristic/incidental distinction 
makes linguistic sense, questions remain as to its practical 
use. In line with the findings from this study, a recent review 
showed that despite an increasingly more coherent under-
standing of placebos in the research community, both health-
care professionals and patients still broadly conceive of 
placebos as inert substances (Hardman et al., 2018). If most 
patients think placebos are ‘inert’ pills having a ‘psychologi-
cal’ effect, is it just too difficult to convince them otherwise?
Furthermore, is it even clinically useful to group together 
such a disparate group of factors under the banner of ‘pla-
cebo effects’? Some researchers may argue that other per-
spectives can offer a better way to understand the 
psychological, social and cultural effects of treatment 
the placebo concept purports to explain. For example, the 
Habermasian lifeworld/medical system distinction 
(Scambler, 2015; Scambler and Britten, 2001), narrative 
medicine (Charon, 2006) or, as previously noted, enactive 
or embodied accounts of healthcare practices.
These questions are beyond the scope of this study, but 
they illustrate that the placebo phenomenon raises impor-
tant questions about modern evidence-based medicine; 
about healing; and about the limits of narrow biomedical 
approaches to healthcare. In addition, whatever one thinks 
of the clinical viability of placebo treatment, the ‘placebo 
effect’ still seems an interesting paradigm in which to con-
sider these important medical issues.
Strengths and limitations of the study
One of the strengths of this study is that by focussing on 
mainstream media articles related to placebos, we were 
able to incorporate a broad range of views. However, there 
are limitations to this approach. In sampling mainstream 
media, there is a risk that marginalised voices are ignored 
– it is important that future research on public perspectives 
on placebos also includes, if possible, a wider range of 
media and other interactional settings. Moreover, the nature 
of the data – short comments – may preclude more nuanced 
reflection by commentators, and this limitation must be 
considered when reflecting on the findings.
Conclusion
Based on our discursive exploration of public perspectives on 
placebos and their effects, we suggest that the dominant way 
in which placebos are constructed – as inert pills – renders 
placebo treatment illogical and deceptive. We also identified 
a counter-discursive construct – the treatment process – 
through which placebo treatment is grounded in the therapeu-
tic encounter. We suggest that through this construct, placebo 
treatment might be productively promoted as part of modern 
evidence-based medicine. However, we also question the 
clinical worth of stretching the concept of placebo treatment 
so far, given the current dominant lay understanding. We 
therefore suggest other theoretical models through which the 
power of the therapeutic encounter might also be exploited.
In doing so, however, we do not necessarily propose that 
researchers should stop investigating the placebo phenom-
enon per se. Merely that by grounding the concept more 
explicitly in the therapeutic encounter, placebo research 
would be more orientated to the particular settings in which 
these ‘placebo effects’ occur. In this sense, we echo recent 
calls for more ethnomethodological or ethnographic field-
work in the domain of placebo research (e.g. Hardman 
et al., 2018; Hutchinson and Moerman, 2018). Such a re-
orientation towards ‘the endogenous methods employed by 
members of societies in the co-production of the order and 
meaning of clinical settings’ (Hutchinson and Moerman, 
2018: 377) may lead to a more fruitful relationship between 
placebo research and clinical practice.
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